cyclotron worker looks into a hotcell:

Sitemap

Please find a full overview of our website below.

  • Home
  • About us
  • Symposium
  • INMiND
  • 89Zr's versatile contribution to nuclear imaging
  • PhD dissertation reports excellent imaging results using 89Zr-labeled antibodies in cancer therapy
  • Marking dextran nanoparticles with 89Zr enables in vivo imaging of macrophages
  • Fresolimumab labeled with 89Zr to evaluate the potential of this TGF-β antibody as a drug for cancer treatment
  • Shedding new light on clinical antibody therapy
  • Optical imaging of Cerenkov light generation from positron-emitting radiotracers
  • Philips installs new PET-Scanner in VUmc
  • New study contributes to the development of (radio)labeled mAb conjugates for photoimmunodetection in cancer
  • PET with [18F]NaF produces better results than [18F]FDG in the assessment of valvular calcification and inflammation in aortic stenosis
  • Reviewing the current status of Iodine-124 in use in the clinical scene
  • Radiolabeling of ibritumomab tiuxetan with 89Zr used to monitor the biodistribution of 90Y-ibritumomab tiuxetan (Zevalin) in radioimmunotherapy
  • News in cancer treatment: application of 89Zr-labeled nanobodies shows potential for therapy and PET imaging of HGF expressing tumors
  • 89Zr-labeled monoclonal antibody panitumumab used in PET and MRI to assess the status of growth factor receptor HER1 in distant metastases of colorectal cancer
  • Successful tumor dosimetry with quantitative iodine-124-PET/CT highly promising as pre-therapy for iodine-131 treatment of neuroblastoma in humans
  • 89Zr-radiolabeled TRC105, a chimeric monoclonal antibody binding CD105 (endoglin), successfully enables PET and Near-Infrared Fluorescence Imaging (NIRF) of 4T1 breast tumors
  • New 89Zr-labeled radiotracer provides clear evidence of the unique virtues of imaging with biomarkers in prostate cancer
  • Clinical dilemma in a breast cancer patient solved with PET imaging of 89Zr-trastuzumab
  • Application of Iodine-124 in bone marrow dosimetry
  • Comparative PET imaging shows similar efficacy of 11C-PiB and 18F-Florbetaben for identification of Alzheimer’s disease patients
  • Stable labeling of nanoparticles with Iodine-124 for targeting endothelial tissues
  • Iodine-124-paclitaxel analogue used to compare drug uptake in sensitive and multidrug resistant cell lines
  • New 89Zr-labeled immuno-PET tracer (Zr-iPET) enables longer monitoring of lymphoma therapy in a humanized transgenic mouse model
  • Addition of 18F-NaF to standard PET/CT procedure enhances tumor detection while reducing costs and radiation burden
  • PET/CT with 18F-NaF used to identify patients benefiting from rescue surgery to relieve recurrent back pain after spinal fusion
  • 89Zr-onartuzumab enables precise, long-lasting PET imaging of the Met receptor in cancer xenografts
  • FDA approves production of Choline-C11 for PET imaging to detect prostate cancer
  • Application of 89Zr- and IRDye800CW-labeled tracers found to be comparable in tissue distribution studies
  • Efficient visualization of CD105-expressing tumors using 89Zr- and IRDye800CW-labeled dual tracer
  • Prospective study reveals diagnostic potential of combined 124I-PET/CT and 18F-FDG-PET/CT in detecting recurrent tumors in DTC patients
  • PET imaging with 89Zr-bevacizumab reveals VEGF-A levels in response to early everolimus treatment in a xenograft model of ovarian cancer
  • Immuno-PET imaging with 124I-labeled girentuximab proves useful in pre-operative diagnosis of clear-cell renal cell carcinoma
  • Use of 89Zr-ImmunoPET successful for imaging of drug-induced apoptosis in tumor treatment targeting phosphatidylserine
  • Treatment with lapatinib and 17AAG shown to reduce the expression of HER2, and consequent uptake of 89Zr-trastuzumab-F(ab’)(2), in SKBR3 xenografts
  • New review article covers the past and the future of PET imaging with 89Zr, from radiochemistry to clinical application
  • Announcement: PerkinElmer to become Cyclotron’s new sales, marketing and distribution partner for 89Zr and 124I
  • Pilot study to test the clinical feasibility of PET/CT lymphoscintigraphy with 89Zr-nanocolloidal albumin for identification of sentinel nodes has positive results
  • 89Zr-labeled panitumumab reveals potential for immuno-PET of HER-1 expressing carcinomas
  • Study validates the use of Cerenkov Luminescence Imaging for evaluation of 89Zr-rituximab in NHL using Humanized Transgenic Mouse Model
  • Visualization of VEGF-A in primary breast cancer patients by PET imaging with 89Zr-bevacizumab
  • PET imaging with 89Zr-bevacizumab successfully applied for visualization of VEGF-A in human atherosclerotic plaque
  • PerkinElmer participates in the SNMMI Annual Meeting in Vancouver, June 8-12
  • 89Zr in review: a radionuclide and its potential for PET imaging
  • Pilot study shows NaF-PET/CT to be more reliable than scintigraphy or SPECT/CT for detection of bone metastases
  • ARTFORCE - 1 Million Euro granted for production and delivery of 89Zr-radiolabeled antibodies
  • Upcoming Webinar: Advancing Discovery and Development of Biologics Through Non-Invasive Biodistribution Imaging
  • BV Cyclotron VU at the EANM 2013, from October 19 to 23 in Lyon, France
  • BV Cyclotron to produce 18F-NeuraCeqTM for the Dutch market in cooperation with Piramal and IBA Molecular
  • Study harmonizes 89Zr-PET/CT performance in multicenter studies
  • Reducing the uptake of 89Zr-labeled bevacizumab
  • 89Zr-PET using different mAbs to detect the effects of a HSP90 inhibitor in patients with metastatic breast cancer
  • Products
  • PET Tracers
  • FDG
  • Research Products
  • Sodium Iodide
  • Sodium Fluoride
  • Fluoromethylcholine
  • Diagnostic Radiochemicals and Radionuclides
  • Zirconium-89
  • Iodine-124
  • Kryptoscan TM: 81Rb/81mKr Generator
  • Devices
  • Type A Transport Container
  • Factsheet Type A Transport Container
  • Research and Development
  • Research Partnerships/VUmc
  • Department of Nuclear Medicine & PET Research
  • Center for Translational Molecular Medicine (CTMM): DeCoDe, LeARN, TRACER
  • INMiND
  • Video Imaging Center
  • Cyclotron White Papers & Presentations
  • Webinar
  • About us
  • Our Company
  • Core Purpose and Values
  • Our Facility
  • Our People
  • Interviews
  • Perry Kruijer - vision
  • Peter van Leuffen - history
  • Some historical notes on our first Cyclotron
  • Our Partners
  • IBA
  • Von Gahlen
  • Our Markets
  • Map of the world with customers
  • References
  • Academic Alliances
  • European Association of Nuclear Medicine
  • Society of Nuclear Medicine (SNM)
  • How to find us?
  • Perry Kruijer
  • Johan van Westendorp
  • Monique Bot
  • Ilona Heerdt
  • Jeroen Groeneweg
  • Roel Mooij
  • Henk Stolker
  • Saskia Trampe-de Keijzer
  • Bart Vogelaar
  • Maria Vosjan
  • Karin Hertgers
  • Uta Funke
  • Prof. Dr. Guus van Dongen
  • Press
  • Services
  • Delivery Map of Europe
  • Production Schedule
  • Recommended Literature
  • Downloads
  • Prof. van Dongen and colleagues
  • Decay calculator
  • Twitter
  • Youtube
  • test
  • Peter van Leuffen